Undisclosed tRNA Epitranscriptomics Program
Oncology
PreclinicalActive
Key Facts
About THERAtRAME
THERAtRAME is an early-stage biotech pioneering a novel approach in oncology by targeting transfer RNA (tRNA) epitranscriptomics with small molecules. The company, spun out from academic research, is developing a platform to discover drugs that interfere with the RNA modification machinery, a process implicated in cancer progression and drug resistance. As a private, preclinical-stage company, it is likely reliant on grant funding and venture capital to advance its research. Its success hinges on validating this emerging biological pathway and translating its discoveries into viable drug candidates.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |